Distinguishing post-treatment changes from recurrent disease in cholangiocarcinoma: a case report

This case report will evaluate the management of bimaxillary protrusion by standard edge wise technique with extraction of premolars. The objective of treatment was to use mild forces and to provide maximum space for the retraction of anterior teeth. The goal of the treatment was to improve facial appearance. The case was successfully managed by extraction of all first Premolars and fixed appliance therapy using standard edge wise mechanics. Post-treatment changes were good and stableBan J Orthod & Dentofac Orthop, April 2013; Vol-3, No.2

Download Full-text

FDG PET/CT findings and post‑treatment changes of COVID‑19 pneumonia in a patient with lymphoma: A case report

Molecular and Clinical Oncology ◽

10.3892/mco.2021.2489 ◽

2021 ◽

Vol 16 (3) ◽

Author(s):

Joy Matsui ◽

Asha Kandathil ◽

Fangyu Peng

Keyword(s):

Case Report ◽

Fdg Pet ◽

Post Treatment ◽

Ct Findings ◽

Pet Ct ◽

Treatment Changes ◽

Fdg Pet Ct

Download Full-text

Rapid growth of myxoid leiomyosarcoma of the vulva during pregnancy: a case report

International Journal of Gynecological Cancer ◽

10.1136/ijgc-00009577-200401000-00026 ◽

2004 ◽

Vol 14 (1) ◽

pp. 172-175 ◽

Cited By ~ 1

Author(s):

A. R. Di Gilio ◽

G. Cormio ◽

L. Resta ◽

C. Carriero ◽

V. Loizzi ◽

...

Keyword(s):

Differential Diagnosis ◽

Smooth Muscle ◽

Case Report ◽

Lymph Node ◽

Cesarean Section ◽

Recurrent Disease ◽

Node Dissection ◽

Smooth Muscle Tumors ◽

Vulvar Mass

Smooth muscle tumors arising in the vulva are rare. Leiomyosarcoma is the most common variant of vulvar sarcoma, and very few cases have been reported during pregnancy. A 36-year-old woman presented with a progressively enlarging vulvar mass during pregnancy, diagnosed as a Bartholin's gland cyst. The lesion was resected at 38 weeks of gestation during cesarean section and diagnosis of myxoid leiomyosarcoma of the vulva was made. Six weeks later the patients were referred to our center and submitted to wide vulvar excision with groin lymph node dissection that revealed the presence of a small residual focus of leiomyosarcoma. At 30 months of follow-up the patient was well without any sign of recurrent disease. Leiomyosarcoma should be included in the differential diagnosis of vulvar masses; progressively enlarging vulvar lesion should be biopsied even during pregnancy. Leiomyosarcoma should be considered in the differential diagnosis of vulvar mass.

Download Full-text

Behavioural Management of Headache Triggers: Three Case Examples Illustrating a New Effective Approach (Learning to Cope with Triggers)

Behaviour Change ◽

10.1017/bec.2015.8 ◽

2015 ◽

Vol 32 (3) ◽

pp. 202-208 ◽

Cited By ~ 5

Author(s):

Paul R. Martin ◽

Moira Callan ◽

Archana Kaur ◽

Karen Gregg

Keyword(s):

Traditional Approach ◽

Tension Type Headache ◽

Post Treatment ◽

Case Examples ◽

Medication Consumption ◽

Alternative Approach ◽

Treatment Changes ◽

Type Headache ◽

Behavioural Management

The traditional approach to headache trigger management is to advise avoidance of all triggers, but we have advocated an alternative approach called ‘Learning to Cope with Triggers’ (LCT), in which the objective is to desensitise headache sufferers to some triggers or to build up tolerance for the triggers, using exposure techniques. A recent publication established the efficacy of this approach to trigger management. Reported here are three cases to illustrate how LCT is used in practice. Two cases were male and one was female, with ages ranging from 32 to 67 years. The headache diagnoses were frequent episodic tension-type headache, migraine without aura, and chronic tension-type headache; all had had headaches since childhood/adolescence. The headache triggers that were the focus of the intervention were heat, tiredness, and stress/anger. Post-treatment, changes in the capacity of the triggers to elicit headaches were reported in all three cases. Reductions in headaches from pre- to post-treatment, and from pre- to 4-month follow-up, were: case 1, 69% and 60% respectively; case 2, 76% and 80% respectively; and case 3, 73% and 61% respectively. Decreases in medication consumption, and enhanced self-efficacy were also recorded.

Download Full-text

Frontotemporal Dementia Misdiagnosed for Post-Treatment Lyme Disease Syndrome or vice versa? A Treviso Dementia (TREDEM) Registry Case Report

Journal of Alzheimer s Disease ◽

10.3233/jad-180524 ◽

2018 ◽

Vol 66 (2) ◽

pp. 445-451

Author(s):

Maria Elena Di Battista ◽

Carola Dell’Acqua ◽

Luciana Baroni ◽

Chiara Fenoglio ◽

Daniela Galimberti ◽

...

Keyword(s):

Case Report ◽

Lyme Disease ◽

Frontotemporal Dementia ◽

Post Treatment

Download Full-text

A qualitative study exploring men’s experience of sexual dysfunction as a result of radiotherapy and androgen deprivation therapy to treat prostate cancer

Journal of Radiotherapy in Practice ◽

10.1017/s1460396920000059 ◽

2020 ◽

pp. 1-4

Author(s):

W. Kinnaird ◽

A. Stewart-Lord

Keyword(s):

Prostate Cancer ◽

Sexual Dysfunction ◽

Qualitative Study ◽

Androgen Deprivation Therapy ◽

Androgen Deprivation ◽

Post Treatment ◽

Self Perception ◽

Treat Prostate Cancer ◽

Treatment Changes ◽

A Priority

Abstract Aim: Sexual dysfunction is a common side effect of external beam radiotherapy (EBRT) and androgen deprivation therapy (ADT) to treat prostate cancer. Men are likely to experience erectile dysfunction, low libido, ejaculatory problems and penile shortening. This qualitative study explored men’s perceptions of sexual dysfunction, including factors such as self-perception, relationships and information and support needs. Methods: Semi-structured interviews were carried out with n = 8 men living 18–30 months after EBRT ± ADT. The interviews were transcribed and thematic analysis was carried out. Results: All men experienced sexual dysfunction following treatment. The main themes arising were: (i) priorities—sexual issues were not a priority when making treatment decisions, (ii) information and support—men described a lack of information and support about sexual dysfunction and (iii) impact—sexual dysfunction impacted on their self-perception and relationships. Findings: Men undergoing EBRT/ADT for prostate cancer may be affected by post-treatment changes in sexual function in a range of ways. This study suggests that they would benefit from early and wide-ranging information and support on sexual dysfunction, even if they do not consider it as a priority. Candid discussions about self-perception and relationships, as well as physical changes, may equip them to cope with post-treatment changes.

Download Full-text

The Role of VEGFA, COX2, HUR and CUGBP2 in Predicting the Response to Neoadjuvant Therapy in Rectal Cancer Patients

Medicina ◽

10.3390/medicina56040192 ◽

2020 ◽

Vol 56 (4) ◽

pp. 192

Author(s):

Henrikas Pauzas ◽

Ugne Gyvyte ◽

Tadas Latkauskas ◽

Laura Kairevice ◽

Paulius Lizdenis ◽

...

Keyword(s):

Gene Expression ◽

Rectal Cancer ◽

Neoadjuvant Therapy ◽

Predictive Value ◽

Post Treatment ◽

Treatment Changes ◽

Pre Treatment ◽

Cox2 Expression ◽

Vegfa Gene

Background and objectives: The effectiveness of neoadjuvant therapy, which is commonly used for stage II-III rectal cancer (RC) treatment, is limited. Genes associated with the pathogenesis of RC could determine response to this treatment. Therefore, the aim of this study was to investigate the potential predictive value of VEGFA, COX2, HUR and CUGBP2 genes and the associations between post-treatment changes in gene expression and the efficacy of neoadjuvant therapy. Materials and Methods: Biopsies from RC and healthy rectal tissue of 28 RC patients were collected before neoadjuvant therapy and 6-8 weeks after neoadjuvant therapy. The expression levels of VEGFA, COX2, HUR, CUGBP2 genes were evaluated using a quantitative real-time polymerase chain reaction. Results: The results reveal a significantly higher expression of VEGFA, COX2 and HUR mRNA in RC tissue compared to healthy rectal tissue (p < 0.05), and elevated VEGFA gene expression in pre-treatment tissues was associated with a better response to neoadjuvant therapy based on T-stage downstaging (p < 0.05). The expression of VEGFA, HUR and CUGBP2 genes significantly decreased after neoadjuvant therapy (p < 0.05). Responders to treatment demonstrated a significantly stronger decrease of VEGFA and COX2 expression after neoadjuvant therapy than non-responders (p < 0.05). Conclusions: The findings of this study suggest that the pre-treatment VEGFA gene expression might have predictive value for the response to neoadjuvant therapy, while the post-treatment decrease in VEGFA and COX2 gene expression could indicate the effectiveness of neoadjuvant therapy in RC patients.

Download Full-text